PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific
Decision brief
Answer first · skim in under a minute
PREMIA and Lind are set to revolutionize clinical trial screening in the Asia-Pacific region through AI technology, presenting significant investment opportunities. This expansion is poised to reshape competitive dynamics in the pharmaceutical industry.
PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific through a May 27, 2026 joint venture called Lind Asia. The deal localizes Lind’s AI screening platform with PREMIA’s clinical-genomic infrastructure for sites in Taiwan, Japan, South Korea, Singapore, and Australia. Leadership planned ASCO partnering meetings May 29 to June 2, 2026.
Contents10 sections
Key Takeaways
- On May 27, 2026, PREMIA and Lind formed Lind Asia as the exclusive Asia-Pacific partner for Lind’s AI trial-screening platform.
- Launch markets named in the release are Taiwan, Japan, South Korea, Singapore, and Australia.
- PREMIA’s earlier LC-SCRUM Asia work cited more than 17,000 patients and 200-plus hospitals for genomic screening and trial matching.
- No independent enrollment speed or screen-failure data were disclosed in the Lind Asia announcement.
What did PREMIA and Lind announce on May 27, 2026?
Precision Medicine Asia, Limited (PREMIA) and Lind formed Lind Asia to speed patient eligibility screening for clinical trials across Asia-Pacific. Lind Asia is the exclusive regional partner for Lind’s AI-powered screening platform and will use PREMIA’s clinical-genomic database experience.
The companies described the deal in a May 27, 2026 GlobeNewswire release. Quotes from PREMIA’s Wenn Sun and Lind CEO Oggie Nikolic framed the goal as fewer screen failures and faster access to new therapies—without publishing quantified timelines.
Which Asia-Pacific markets are in scope?
Lind’s platform will be localized for healthcare institutions in five named markets: Taiwan, Japan, South Korea, Singapore, and Australia. That list is the concrete geographic claim sponsors can track in 2026 partnering discussions.
Lind and Lind Asia leadership said they would attend the American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2, 2026, to discuss recruitment timelines with trial teams.
How does PREMIA’s genomic network fit AI screening?
PREMIA has long positioned clinical-genomic registries as a route to faster oncology trial matching in Asia. A December 21, 2022 GlobeNewswire release on LC-SCRUM-AP said the Japan registry then included more than 17,000 patients and more than 200 hospitals in Japan and Taiwan, with Southeast Asia expansion planned.
- 17,000-plus patients cited in the 2022 LC-SCRUM Asia registry update
- 200-plus participating hospitals named in that release
- 2022 launch year for the LC-SCRUM-AP Asia-Pacific expansion track
Why trial screening tools matter for sponsors
Recruitment remains a bottleneck on public registries such as ClinicalTrials.gov, where sponsors list eligibility criteria that sites must match patient by patient. AI screening that reads electronic health records can narrow the candidate pool before manual chart review.
Separately, the U.S. FDA’s June 26, 2024 draft guidance on Diversity Action Plans pushes sponsors of certain pivotal studies to set enrollment goals by age, sex, race, and ethnicity and to describe how they will meet them. Tools that surface eligible patients across more sites can support those plans, but they do not replace the plan itself.
What Lind Asia says the platform will do
Trade coverage of the joint venture summarized three pillars: AI patient identification from structured and unstructured EHR data, a research-ready regional site network, and integrated molecular profiling for biomarker-driven matching. Those pillars align with PREMIA’s genomic-network history and Lind’s screening software pitch.
Sponsors should treat the pillars as product claims until Lind Asia publishes site counts, validation studies, or protocol-level enrollment metrics on an independent registry or peer-reviewed study.
What remains unproven after the launch release
The May 27, 2026 announcement does not report percent reductions in screen failures, days saved to first patient in, or how many hospitals have live deployments. Older PREMIA registry figures (17,000-plus patients; 200-plus hospitals) describe genomic screening reach, not Lind Asia AI outcomes.
Until those numbers appear in primary filings or trial records, buyers should ask for validation datasets and pilot protocols rather than assuming APAC-wide recruitment gains.
Related NovaPharma coverage
- PREMIA and Lind Launch Lind Asia to Revolutionize Clinical Trials with AI
- ASCO 2026: Asian Oncology Innovation Takes Center Stage
- Asia Pacific eClinical Solutions Market Report 2025-2030
Frequently Asked Questions
When did PREMIA and Lind announce Lind Asia?
On May 27, 2026, Precision Medicine Asia (PREMIA) and Lind announced the formation of Lind Asia, a joint venture for AI-powered clinical trial screening in Asia-Pacific.
Which markets will Lind Asia cover first?
Lind said the platform will be localized for healthcare institutions in Taiwan, Japan, South Korea, Singapore, and Australia, with Lind Asia as the exclusive regional partner.
What remains unproven about the Lind Asia launch?
The May 27, 2026 release states partnership scope and goals but does not publish enrollment speed gains, screen-failure rates, or site counts. Those outcomes need independent trial metrics after deployment.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
